These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 38253313)

  • 1. Immunogenicity and safety of concomitant bivalent COVID-19 and quadrivalent influenza vaccination: implications of immune imprinting and interference.
    Choi MJ; Yu YJ; Kim JW; Ju HJ; Shin SY; Yang YJ; Cheong HJ; Kim WJ; Kim C; Kim HJ; Yoon SK; Park SJ; Gwak W; Lee JW; Kim B; Song JY
    Clin Microbiol Infect; 2024 May; 30(5):653-659. PubMed ID: 38253313
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity and safety of a bivalent (omicron BA.5 plus ancestral) SARS-CoV-2 recombinant spike protein vaccine as a heterologous booster dose: interim analysis of a phase 3, non-inferiority, randomised, clinical trial.
    Bennett C; Woo W; Bloch M; Cheung K; Griffin P; Mohan R; Deshmukh S; Arya M; Cumming O; Neville AM; McCallum Pardey TG; Plested JS; Cloney-Clark S; Zhu M; Kalkeri R; Patel N; Marcheschi A; Swan J; Smith G; Cho I; Glenn GM; Walker R; Mallory RM;
    Lancet Infect Dis; 2024 Jun; 24(6):581-593. PubMed ID: 38460525
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity and safety of different combinations involving a third booster dose of SARS-CoV-2 inactivated vaccine, inactivated quadrivalent influenza vaccine, and 23-valent pneumococcal polysaccharide vaccine in adults aged ≥60 years: a phase 4, randomized, open-label study.
    Bai S; Zhou S; Zhang J; Chen W; Lv M; Wang J; Zhang A; Wu J; Zhao W
    Front Immunol; 2024; 15():1437267. PubMed ID: 39229259
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and immunogenicity of a high-dose quadrivalent influenza vaccine administered concomitantly with a third dose of the mRNA-1273 SARS-CoV-2 vaccine in adults aged ≥65 years: a phase 2, randomised, open-label study.
    Izikson R; Brune D; Bolduc JS; Bourron P; Fournier M; Moore TM; Pandey A; Perez L; Sater N; Shrestha A; Wague S; Samson SI
    Lancet Respir Med; 2022 Apr; 10(4):392-402. PubMed ID: 35114141
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and immunogenicity of a modified mRNA-lipid nanoparticle vaccine candidate against COVID-19: Results from a phase 1, dose-escalation study.
    Essink BJ; Shapiro C; Isidro MGD; Bradley P; Pragalos A; Bloch M; Santiaguel J; Frias MV; Miyakis S; Alves de Mesquita M; Berrè S; Servais C; Waugh N; Hoffmann C; Baba E; Schönborn-Kellenberger O; Wolz OO; Koch SD; Ganyani T; Boutet P; Mann P; Mueller SO; Ramanathan R; Gaudinski MR; Vanhoutte N
    Hum Vaccin Immunother; 2024 Dec; 20(1):2408863. PubMed ID: 39422261
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and immunogenicity against ancestral, Delta and Omicron virus variants following a booster dose of an inactivated whole-virus COVID-19 vaccine (VLA2001): Interim analysis of an open-label extension of the randomized, controlled, phase 3 COV-COMPARE trial.
    Taucher C; Lazarus R; Dellago H; Maurer G; Weisova P; Corbic-Ramljak I; Dubischar K; Lilja A; Eder-Lingelbach S; Hochreiter R; Jaramillo JC; Junker H; Krammer M; Pusic P; Querton B; Larcher-Senn J; Hoffmann M; Pöhlmann S; Finn A;
    J Infect; 2023 Sep; 87(3):242-254. PubMed ID: 37406777
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial.
    Wu S; Huang J; Zhang Z; Wu J; Zhang J; Hu H; Zhu T; Zhang J; Luo L; Fan P; Wang B; Chen C; Chen Y; Song X; Wang Y; Si W; Sun T; Wang X; Hou L; Chen W
    Lancet Infect Dis; 2021 Dec; 21(12):1654-1664. PubMed ID: 34324836
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bivalent Omicron BA.4/BA.5 BNT162b2 Vaccine in 6-Month- to <12-Year-Olds.
    Sher LD; Boakye-Appiah JK; Hill S; Wasserman E; Xu X; Maldonado Y; Walter EB; Muñoz FM; Paulsen GC; Englund JA; Talaat KR; Barnett ED; Kamidani S; Senders S; Simões EAF; Belanger K; Parikh V; Ma H; Wang X; Lu C; Cooper D; Koury K; Anderson AS; Türeci Ö; Şahin U; Swanson KA; Gruber WC; Gurtman A; Kitchin N; Sabharwal C
    J Pediatric Infect Dis Soc; 2024 Aug; 13(8):421-429. PubMed ID: 38860591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Omicron BA.1-containing mRNA-1273 boosters compared with the original COVID-19 vaccine in the UK: a randomised, observer-blind, active-controlled trial.
    Lee IT; Cosgrove CA; Moore P; Bethune C; Nally R; Bula M; Kalra PA; Clark R; Dargan PI; Boffito M; Sheridan R; Moran E; Darton TC; Burns F; Saralaya D; Duncan CJA; Lillie PJ; San Francisco Ramos A; Galiza EP; Heath PT; Girard B; Parker C; Rust D; Mehta S; de Windt E; Sutherland A; Tomassini JE; Dutko FJ; Chalkias S; Deng W; Chen X; Feng J; Tracy L; Zhou H; Miller JM; Das R;
    Lancet Infect Dis; 2023 Sep; 23(9):1007-1019. PubMed ID: 37348519
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Booster vaccination using bivalent DS-5670a/b is safe and immunogenic against SARS-CoV-2 variants in children aged 5-11 years: a phase 2/3, randomized, active-controlled study.
    Suzuki R; Suda M; Ishida K; Furihata K; Ota A; Takahashi K; Sakakibara S; Nakayama T; Takeshita F
    Front Immunol; 2024; 15():1445459. PubMed ID: 39286253
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative immunogenicity of monovalent and bivalent adenovirus vaccines carrying spikes of early and late SARS-CoV-2 variants.
    Li H; Yang C; Yin L; Liu W; Zhang Z; Liu B; Sun X; Liu W; Lin Z; Liu Z; He P; Feng Y; Wang C; Wang W; Guan S; Wang Q; Chen L; Li P
    Emerg Microbes Infect; 2024 Dec; 13(1):2387447. PubMed ID: 39082740
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity and Safety of Heterologous Omicron BA.1 and Bivalent SARS-CoV-2 Recombinant Spike Protein Booster Vaccines: A Phase 3 Randomized Clinical Trial.
    Bennett C; Rivers EJ; Woo W; Bloch M; Cheung K; Griffin P; Mohan R; Deshmukh S; Arya M; Cumming O; Neville AM; Pardey TM; Plested JS; Cloney-Clark S; Zhu M; Kalkeri R; Patel N; Buchanan A; Marcheschi A; Swan J; Smith G; Cho I; Glenn GM; Walker R; Mallory RM
    J Infect Dis; 2024 Jul; 230(1):e4-e16. PubMed ID: 39052718
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interim safety and immunogenicity analysis of the EuCorVac-19 COVID-19 vaccine in a Phase 3 randomized, observer-blind, immunobridging trial in the Philippines.
    Lovell JF; Miura K; Baik YO; Lee C; Choi Y; Her H; Lee JY; Ylade M; Lee-Llacer R; De Asis N; Trinidad-Aseron M; Ranola JM; De Jesus LZ
    J Med Virol; 2024 Sep; 96(9):e29927. PubMed ID: 39318203
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An Omicron-specific, self-amplifying mRNA booster vaccine for COVID-19: a phase 2/3 randomized trial.
    Saraf A; Gurjar R; Kaviraj S; Kulkarni A; Kumar D; Kulkarni R; Virkar R; Krishnan J; Yadav A; Baranwal E; Singh A; Raghuwanshi A; Agarwal P; Savergave L; Singh S;
    Nat Med; 2024 May; 30(5):1363-1372. PubMed ID: 38637636
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and Immunogenicity of Respiratory Syncytial Virus Prefusion F Protein Vaccine when Co-administered with Adjuvanted Seasonal Quadrivalent Influenza Vaccine in Older Adults: A Phase 3 Randomized Trial.
    Clark R; Davies S; Labrador J; Loubet P; Natalini Martínez S; Moríñigo HM; Nicolas JF; Vera MP; Rämet M; Rebollo-Rodrigo MH; Sanz-Muñoz I; Dezutter N; Germain S; David MP; Jayadev A; Amare Hailemariam H; Kotb S; Meyer N
    Clin Infect Dis; 2024 Oct; 79(4):1088-1098. PubMed ID: 39099085
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity of COVID-19 booster vaccination in IEI patients and their one year clinical follow-up after start of the COVID-19 vaccination program.
    van Leeuwen LPM; Grobben M; GeurtsvanKessel CH; Ellerbroek PM; de Bree GJ; Potjewijd J; Rutgers A; Jolink H; van de Veerdonk FL; van Gils MJ; de Vries RD; Dalm VASH;
    Front Immunol; 2024; 15():1390022. PubMed ID: 38698851
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the UK (ComFluCOV): a multicentre, randomised, controlled, phase 4 trial.
    Lazarus R; Baos S; Cappel-Porter H; Carson-Stevens A; Clout M; Culliford L; Emmett SR; Garstang J; Gbadamoshi L; Hallis B; Harris RA; Hutton D; Jacobsen N; Joyce K; Kaminski R; Libri V; Middleditch A; McCullagh L; Moran E; Phillipson A; Price E; Ryan J; Thirard R; Todd R; Snape MD; Tucker D; Williams RL; Nguyen-Van-Tam JS; Finn A; Rogers CA;
    Lancet; 2021 Dec; 398(10318):2277-2287. PubMed ID: 34774197
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The safety, immunogenicity, and efficacy of heterologous boosting with a SARS-CoV-2 mRNA vaccine (SYS6006) in Chinese participants aged 18 years or more: a randomized, open-label, active-controlled phase 3 trial.
    Zhou C; Qiu Y; Wang J; Zhong X; Zhu X; Huang X; Yang L; Ji Q; Zhou F; Wu S; Yang M; Zhang J; Liu K; Ji L; Yang H; Li C; Zhao Y
    Emerg Microbes Infect; 2024 Dec; 13(1):2320913. PubMed ID: 38860446
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Bivalent Omicron-BA.4/BA.5-Adapted BNT162b2 Booster in ≥12-Year-Olds.
    Usdan L; Patel S; Rodriguez H; Xu X; Lee DY; Finn D; Wyper H; Lowry FS; Mensa FJ; Lu C; Cooper D; Koury K; Anderson AS; Türeci Ö; Şahin U; Swanson KA; Gruber WC; Kitchin N;
    Clin Infect Dis; 2024 May; 78(5):1194-1203. PubMed ID: 38016021
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety, immunogenicity, and efficacy of a COVID-19 vaccine (NVX-CoV2373) co-administered with seasonal influenza vaccines: an exploratory substudy of a randomised, observer-blinded, placebo-controlled, phase 3 trial.
    Toback S; Galiza E; Cosgrove C; Galloway J; Goodman AL; Swift PA; Rajaram S; Graves-Jones A; Edelman J; Burns F; Minassian AM; Cho I; Kumar L; Plested JS; Rivers EJ; Robertson A; Dubovsky F; Glenn G; Heath PT;
    Lancet Respir Med; 2022 Feb; 10(2):167-179. PubMed ID: 34800364
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.